Cytokinetics sues Bristol Myers Squibb over recently granted patent, intensifying rivalry

Cytokinetics has filed a lawsuit against Bristol Myers Squibb, seeking to invalidate a patent that was recently granted to the latter.

The legal action adds a courtroom dimension to an already competitive relationship between the two companies in the pharmaceutical market.

Cytokinetics aims to challenge the patent’s validity, which could affect Bristol Myers Squibb’s ability to protect related products.

The case highlights the growing importance of intellectual property disputes in the industry, though no outcome has been decided yet.